Brain Cancer

Formerly "Brain and CNS Cancers"

Brain Cancer

Addition of Temodar® to Radiation in Glioma: New Standard of Care (January 19, 2017)

The addition of the chemotherapy agent, Temodar® (temozolomide), to radiation therapy has demonstrated a huge survival benefit compared to treatment with radiation therapy alone among patients with newly... Continue Reading

Can Lasers Be Used to Treat ‘Inoperable’ Brain Tumors? (December 7, 2016)

Brain surgery to remove many tumors is often complicated in that surgery will damage areas of the brain necessary for many essential life skills and functions. Delivery of chemotherapy or radiation can... Continue Reading

Temodar® After Radiation Improves Survival in Anaplastic Gliomas (June 7, 2016)

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic... Continue Reading

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma (May 23, 2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an... Continue Reading

Avastin®/Camptosar® Improves Outcomes Compared with Temodar® in Glioblastoma (May 12, 2016)

The treatment combination consisting of Avastin (bevacizumab) plus Camptosar (irinotecan) improves time to cancer progression compared to treatment with Temodar (temozolomide) in patients with newly diagnosed... Continue Reading

Data Safety and Monitoring Board Recommends Celldex’s Phase 3 Study of RINTEGA® in Newly Diagnosed Glioblastoma Be Discontinued (March 7, 2016)

Celldex Therapeutics, Inc. announced today that the independent Data Safety and Monitoring Board (DSMB) has determined, based on a preplanned interim analysis, that continuation of the Phase 3 ACT IV study... Continue Reading

Immune Therapy for Brain Tumors: A New Promising Avenue (February 17, 2016)

Immune Therapy for Brain Tumors: A New Promising Avenue Glioblastoma is a particularly aggressive type of brain cancer. Only about one-fifth of adults diagnosed with it survive two years or more after... Continue Reading

Combination of Radiation and Chemotherapy Improves Survival For Certain Types of Brain Cancer (January 29, 2016)

Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review Patients with a low-grade type of brain cancer known as low grade glioma may live up to five and a half years longer when... Continue Reading

Long-Term Survival Benefit Demonstrated with RINTEGA® in Recurrent Glioblastoma (November 24, 2015)

Mature survival data from a randomized, double-blind Phase 2 clinical study evaluating RINTEGA® (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma (GBM) were recently presented... Continue Reading

GBM AGILE: A Next-Generation Clinical Trial for Brain Cancer (November 13, 2015)

Glioblastoma Multiforme (GBM) is a devastating disease. The deadliest and most aggressive form of brain tumor, GBM is expected to claim the lives of 12,000 people in the United States this year, plus tens... Continue Reading

Optune Approved for Newly Diagnosed Glioblastoma Multiforme (October 22, 2015)

The United States Food and Drug Administration has expanded the approval of the Optune device for the treatment of patients with newly diagnosed glioblastoma multiforme. Glioblastoma multiforme (GBM) is... Continue Reading

Ask the Expert! Adult Primary Brain Tumors & Brain Metastases (October 7, 2015)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Lee CancerConnect recently partnered with Dana-Farber Cancer Institute to provide you with the opportunity to engage with... Continue Reading

Could Aspirin Treat Breast Cancer? (October 5, 2015)

Researchers from Dana-Farber Cancer Institute and Brigham and Women’s Hospital (BWH) have received a $10 million Breakthrough Award from the Department of Defense’s Office of the Congressionally Directed... Continue Reading

FDA Grants Fast Track Designation to Toca 511 & Toca FC for Treatment of High Grade Glioblastoma (July 16, 2015)

Tocagen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product, Toca 511 & Toca FC, for the treatment of recurrent high... Continue Reading

Ludwig Cancer Research and Cancer Research Institute Evaluate Immunotherapeutic Strategies for Brain Cancer and Other Types of Solid Tumors (July 14, 2015)

The trials are being conducted through the CVC Clinical Trials Network in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. The CVC Clinical Trials Network... Continue Reading

Researchers Recruit Herpes Virus as Part of Brain Cancer Treatment (July 13, 2015)

A therapy that uses the herpes virus to make tumors more vulnerable to treatment appears promising in the treatment of glioblastoma multiforme (GBM), a form of brain cancer. These findings were presented... Continue Reading

Rintega® Improves Survival in Patients with Glioblastoma Multiforme (July 1, 2015)

The immunotherapy drug Rintega® (rindopepimut) appears to improve survival among patients with relapsed glioblastoma multiforme (GBM) brain cancer. These findings were presented at 2015 Annual Meeting... Continue Reading

MD Anderson Researchers Show Risks of Whole Brain Radiation Therapy Added to Radiosurgery Outweigh Benefits In Patients With Limited Brain Metastases (June 10, 2015)

Radiation oncology researchers from The University of Texas MD Anderson Cancer Center (MD Anderson CC), presented results from a Phase III randomized clinical trial studying the effects of Whole Brain... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS